Merck & Co. saw a peak in its stock price after an upgrade by Deutsche Bank. The bank expects a growth of 26% despite the patent challenges of Keytruda. After a sell-off, the stock price hit a 52-week high. Other firms like Rockland Trust Co., Savvy Advisors Inc., Mraz Amerine & Associates Inc, Wealthfront Advisers LLC, and Campock Group LLC bolstered their positions in Merck. As a result, the company experienced an increase in investor attention. Public Sector Pension Investment Board and Rhumbline Advisers lowered their shares in Merck & Co. Merck's pipeline building is showing momentum despite the lighter FY26 guide. The company received FDA Approval for its drug, KEYTRUDA, and also experienced success in its new Ovarian Cancer venture. Despite some fluctuations, its 2025-2030 outlook remains optimistic. Yet, there are concerns over the stock's long-term value and overvaluation after recent share price strength.
Merck Stocks News Analytics from Tue, 29 Jul 2025 07:00:00 GMT to Sat, 14 Feb 2026 22:21:00 GMT - Rating 7 - Innovation 5 - Information 8 - Rumor 6
